Hurdles in tissue engineering/regenerative medicine product commercialization: A pilot survey of governmental funding agencies and the financial industry

Tissue Engineering - Part A

Volumn 18, Issue 21-22, 2012, Pages 2187-2194

  Bertram, Timothy A ^a,i   Tentoff, Edward ^b   Johnson, Peter C ^c,d,i   Tawil, Bill ^e,f,i   Van Dyke, Mark ^g,i   Hellman, Kiki B ^h,i  

^a Research and Development Tengion Inc   (United States)

^b Piper Jaffray Company   (United States)

^c Avery Dennison Medical Products Division   (United States)

^d Chugai USA LLC   (United States)

^e BAXTER HEALTHCARE CORPORATION   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h Hellman Group LLC   (United States)

ⁱ TERMIS AM Industry Committee ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRANSLATION; CO-DEVELOPMENT; FINANCIAL ENVIRONMENTS; FINANCIAL INDUSTRY; FUNDING AGENCIES; GOVERNMENTAL AGENCY; INTERNATIONAL SOCIETY; INVESTMENT STRATEGY; MEDICAL COMPANIES; MEDICAL TECHNOLOGIES; MEDICINE PRODUCTS; NEW PRODUCT; PILOT SURVEYS; POTENTIAL TECHNOLOGIES; PUBLIC INVESTORS; REGENERATIVE MEDICINE; REGULATORY PATHWAY; RISK TOLERANCE; START-UP COMPANIES; TECHNOLOGY CHOICES; TECHNOLOGY COMMERCIALIZATIONS;

INDUSTRY; INVESTMENTS; LIFE CYCLE; TECHNOLOGY; TISSUE; TISSUE ENGINEERING;

SURVEYS;

ARTICLE; DECISION MAKING; ECONOMICS; FINANCIAL MANAGEMENT; GOVERNMENT; HUMAN; INFORMATION PROCESSING; INVESTMENT; ORGANIZATION; ORGANIZATION AND MANAGEMENT; REGENERATIVE MEDICINE; STATISTICS; TECHNOLOGY; TISSUE ENGINEERING;

DATA COLLECTION; DECISION MAKING; FINANCING, GOVERNMENT; GOVERNMENT AGENCIES; HUMANS; INVESTMENTS; ORGANIZATIONS; PRIVATE SECTOR; PUBLIC SECTOR; REGENERATIVE MEDICINE; TECHNOLOGY TRANSFER; TISSUE ENGINEERING;

EID: 84868574672     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2012.0186     Document Type: Article

References (10)

1. Johnson, P.C., Bertram, T.A., Tawil, B., and Hellman, K.B. Hurdles in tissue engineering/regenerative medicine product commercialization: a survey of North American academia and industry. Tissue Eng Part A 17, 5, 2011.
2. Hellman, K.B., Johnson, P.C., Bertram, T.A., and Tawil, B. Challenges in tissue engineering and regenerative medicine product commercialization: building an industry. Tissue Eng Part A 17, 1, 2011.
3. Lysaght, M.J., Jaklenec, A., and Deweerd, E. Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics. Tissue Eng Part A 14, 305, 2008.
4. Lysaght, M.J., and Hazlehurst, A.L. Tissue engineering: the end of the beginning. Tissue Eng 10, 309, 2004.
5. Lysaght, M.J., and Hazlehurst, A.L. Private sector development of stem cell technology and therapeutic cloning. Tissue Eng 9, 555, 2003.
6. Lysaght, M.J., and Reyes, J. The growth of tissue engineering. Tissue Eng 7, 485, 2001.
7. Lysaght, M.J., Nguy, N.A., and Sullivan, K. An economic survey of the emerging tissue engineering industry. Tissue Eng 4, 23, 1998.
8. Lysaght, M.J. Product development in tissue engineering. Tissue Eng 1, 221, 1995.
9. Johnson, P.C., Mikos, A.G., Fisher, J.P., and Jansen, J.A. Strategic directions in tissue engineering. Tissue Eng 13, 2827, 2007.
10. Brindley, D.A., Davie, N.L., Sahlman, W.A., Bonfiglio, G.A., Culme-Seymour, E.J., Reeve, B.C., and Mason, C. Promising growth and investment in the cell therapy industry during first quarter of 2012. Cell Stem Cell 10, 492, 2012.